<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644874</url>
  </required_header>
  <id_info>
    <org_study_id>PROGNOSIS-G8</org_study_id>
    <secondary_id>R247-A14382</secondary_id>
    <secondary_id>20/ 17768</secondary_id>
    <nct_id>NCT04644874</nct_id>
  </id_info>
  <brief_title>Geriatric Oncology Screening of Older Patients With Solid Cancers</brief_title>
  <acronym>PROGNOSIS-G8</acronym>
  <official_title>Predictive Value of Geriatric Oncology Screening and Geriatric Assessment in Older Patients With Solid Cancers: A Prospective G8 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy of Geriatric Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Older patients with cancer constitute a heterogeneous group with varying comorbidity;&#xD;
      therefore, geriatric assessment with initial screening is recommended. The Geriatric 8 (G8)&#xD;
      has been established as a promising screening tool. Currently, there are no guidelines for&#xD;
      oncogeriatric screening in older cancer patients in Denmark. We hypothesize that by screening&#xD;
      persons age 70 years or more with newly diagnosed cancer, with the G8, we can assess the&#xD;
      prognostic value and identify a subgroup of patients who will benefit from a CGA.&#xD;
&#xD;
      Aims:&#xD;
&#xD;
        -  Determine whether Danish cancer patients, with a G8 score of ≤14, experience poorer&#xD;
           quality of life (QoL), receive less recommended standard cancer treatment, experience&#xD;
           more treatment-related toxicity, stop treatment earlier, and experience shorter survival&#xD;
           than patients with a G8 score &gt;14.&#xD;
&#xD;
        -  Ascertain whether the standard G8 cut-off score of ≤14 is the most relevant cut-off&#xD;
           score, with respect to treatment adherence, treatment-related toxicity, QoL, and&#xD;
           survival, when focusing on the older Danish cancer patient population.&#xD;
&#xD;
        -  Establish whether the performance and prognostic value of the G8 can be strengthened&#xD;
           through the addition of a functional measure, the 30-second chair stand test (30-CST),&#xD;
           and/ or the handgrip strength test (HGST).&#xD;
&#xD;
        -  Evaluate the prognostic value of the modified Geriatric 8 (mG8)&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      A prospective, descriptive study of all outpatients with newly diagnosed solid tumors at the&#xD;
      Department of Oncology, Odense University Hospital, age 70 years or more. Patients will be&#xD;
      screened with the G8, mG8, 30-CST, HGST, and QoL questionnaires at baseline with subsequent&#xD;
      one-year follow-up, to determine the prognostic value of the G8 and the mG8. An initial&#xD;
      two-month pilot study will help determine inclusion rates and highlight necessary practical&#xD;
      adjustments to ensure optimal study participation. Baseline characteristics will be compared&#xD;
      with descriptive statistics. Our primary endpoint; Global Health status/ QoL (EORTC QLQ-C30 &amp;&#xD;
      QLQ-ELD14), and secondary endpoints; treatment adherence, and treatment-related toxicity,&#xD;
      will be assessed using logistical regression; while secondary endpoints; overall survival,&#xD;
      cancer-specific survival, will be assessed using the Kaplan Meier analysis and Cox&#xD;
      proportional hazard models. Post hoc diagnostic performance analysis will be conducted to&#xD;
      determine the optimal G8 cut-off and whether functional measures (30-CST and HGST) can&#xD;
      enhance screening accuracy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global health status / Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Global health status will be described using EORTC QLQ-C30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL)</measure>
    <time_frame>12 months</time_frame>
    <description>HRQoL is measured by EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL)</measure>
    <time_frame>12 months</time_frame>
    <description>HRQoL is measured by EORTC QLQ-ELD14 (ELderly Cancer Patients Module)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Overall Survival is measured from Geriatric 8 screening to time of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-specific Survival</measure>
    <time_frame>12 months</time_frame>
    <description>Cancer-specific Survival is measured from Geriatric 8 screening to time of death in patients with residual cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to initial oncologic treatment plan</measure>
    <time_frame>12 months</time_frame>
    <description>Deviation from initial oncologic treatment plan with the registration of dose reductions, with the given dose measured as a percentage of the planned dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to initial oncologic treatment plan</measure>
    <time_frame>12 months</time_frame>
    <description>Deviation from initial oncologic treatment plan with the registration of dose delays, measured in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to initial oncologic treatment plan</measure>
    <time_frame>12 months</time_frame>
    <description>Deviation from initial oncologic treatment plan with the registration of discontinuation of treatment, measured as the number of given cycles divided by the number of planned cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance analysis of the Geriatric 8</measure>
    <time_frame>12 months</time_frame>
    <description>Performance analysis will be conducted using patients allocated to Comprehensive Geriatric Assessment (CGA), where an abnormal CGA will be defined as &gt;1 abnormal domain, in accordance with the Danish version of the Geriatric Core Dataset (G-Code).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Solid Carcinoma</condition>
  <condition>Frailty</condition>
  <condition>Age</condition>
  <condition>Geriatrics</condition>
  <condition>Screening</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Older cancer patients</arm_group_label>
    <description>All outpatients, age 70 years or more, with solid malignancies, referred to the Department of Oncology at Odense University Hospital for 1st line antineoplastic treatment or information,</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Geriatric 8</intervention_name>
    <description>The G8 is an eight-item screening tool, developed for older cancer patients. The G8 score ranges from 0 (heavily impaired) to 17 (not at all impaired), with a cut-off for potential frailty of ≤14.</description>
    <arm_group_label>Older cancer patients</arm_group_label>
    <other_name>G8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>modified Geriatric 8</intervention_name>
    <description>The mG8 is a modified version of the Geriatric 8 screening tool, consisting of 6-items. The mG8 score ranges from 0 (not at all impaired) to 35 (heavily impaired), with a cut-off for potential frailty at ≥6.</description>
    <arm_group_label>Older cancer patients</arm_group_label>
    <other_name>mG8</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>30 second chair stand test</intervention_name>
    <description>Repetitions within 30 seconds</description>
    <arm_group_label>Older cancer patients</arm_group_label>
    <other_name>30s-CST</other_name>
    <other_name>chair stand test</other_name>
    <other_name>30 CST</other_name>
    <other_name>CST</other_name>
    <other_name>sit-to-stand test</other_name>
    <other_name>30 s chair stand test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Handgrip Strength Test</intervention_name>
    <description>Measured in kilograms</description>
    <arm_group_label>Older cancer patients</arm_group_label>
    <other_name>HGST</other_name>
    <other_name>HST</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All outpatients, age 70 years or more with solid malignancies, referred to the Department&#xD;
        of Oncology at Odense University Hospital for antineoplastic treatment or information&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients age ≥70 with solid tumors (not hematological malignancies nor non-melanoma&#xD;
             skin cancer) referred to the outpatient clinic at Odense University Hospital for&#xD;
             information and/or antineoplastic treatment&#xD;
&#xD;
          -  Patients must be able to give informed consent&#xD;
&#xD;
          -  Patients must be able to speak English or Danish&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have received antineoplastic treatment for another cancer diagnosis&#xD;
             within the past year&#xD;
&#xD;
          -  Patients who have begun chemotherapy or immunotherapy for the referred cancer&#xD;
             diagnosis, more than 48 hours prior to the time of consent&#xD;
&#xD;
          -  Patients who have begun other antineoplastic treatment (not endocrine) for the&#xD;
             referred cancer diagnosis, more than 7 days prior to the time of consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Ewertz, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>University of Southern Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesper Ryg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Geriatric Medicin, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cecilia M Lund, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Clinical Medicin, Herlev and Gentofte Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trine L Jørgensen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Pfieffer, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrik J Ditzel, MD, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Oncology, Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helena M Ditzel, MD</last_name>
    <phone>004542723028</phone>
    <email>helena.mogelbjerg.ditzel@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trine L Jørgensen, MD, PhD</last_name>
    <phone>004540768360</phone>
    <email>Trine.Joergensen@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <state>Fyn</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena M Ditzel, M.D.</last_name>
      <phone>42723028</phone>
      <email>helena.mogelbjerg.ditzel@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Helena Ditzel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Older adults</keyword>
  <keyword>Cancer patients</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Frailty</keyword>
  <keyword>Comprehensive geriatric assessment</keyword>
  <keyword>Geriatric screening</keyword>
  <keyword>Geriatric 8</keyword>
  <keyword>modified Geriatric 8</keyword>
  <keyword>G8</keyword>
  <keyword>mG8</keyword>
  <keyword>elderly</keyword>
  <keyword>screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

